Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label study of S241656 (BDTX-4933) in RAS/MAPK-mutant advanced solid tumors
CTR20262552Phase 2Active
- Sponsor
- Servier
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bdtx-4933 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC), colorectal cancer (CRC), biliary cancer, sponsored by Servier. Started Sep 2023; status: active.
02
Drugs
bdtx-4933
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)biliary cancer
Beyond the preview
Go deeper on CTR20262552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262552.